A ‘smashing’ solution for cancer therapy
Dexmedetomidine cuts perioperative respiratory adverse events in tonsillectomy
9 August 2022In US, hepatitis C often untreated because of ‘barriers’ to care
9 August 2022A ‘smashing’ solution for cancer therapy
Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy. However, when this function is inhibited for an extended period of time, autoimmune diseases may develop.
